A
Anders Elm Pedersen
Researcher at University of Copenhagen
Publications - 91
Citations - 2788
Anders Elm Pedersen is an academic researcher from University of Copenhagen. The author has contributed to research in topics: T cell & Immunotherapy. The author has an hindex of 31, co-authored 90 publications receiving 2491 citations. Previous affiliations of Anders Elm Pedersen include Copenhagen University Hospital & Bispebjerg Hospital.
Papers
More filters
Journal ArticleDOI
Seromic profiling of colorectal cancer patients with novel glycopeptide microarray
Johannes W. Pedersen,Ola Blixt,Eric P. Bennett,Mads Agervig Tarp,Imran Dar,Ulla Mandel,Steen Seier Poulsen,Anders Elm Pedersen,Susanne Rasmussen,Per Jess,Henrik Clausen,Hans H. Wandall +11 more
TL;DR: Evidence for the value of glycopeptides and other PTM‐peptide arrays in diagnostic measures is provided and validated as authentic cancer immunogens by showing expression of the epitopes in cancer using novel monoclonal antibodies.
Journal ArticleDOI
ExStroke Pilot Trial of the effect of repeated instructions to improve physical activity after ischaemic stroke: a multinational randomised controlled clinical trial
Gudrun Boysen,Lars-Henrik Krarup,Xianrong Zeng,Adam Oskedra,Janika Kõrv,Grethe Andersen,Christian Gluud,Anders Elm Pedersen,Marianne Pia Lindahl,Lotte Hansen,Per Winkel,Thomas Truelsen +11 more
TL;DR: Repeated encouragement and verbal instruction in being physically active did not lead to a significant increase in physical activity measured by the PASE score, and more intensive strategies seem to be needed to promote physical activity after ischaemic stroke.
Journal ArticleDOI
CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening
Mingjun Wang,Kasper Lamberth,Mikkel Harndahl,Gustav Røder,Anette Stryhn,Mette Voldby Larsen,Morten Nielsen,Claus Lundegaard,Sheila T. Tang,Morten Hanefeld Dziegiel,Jørgen Rosenkvist,Anders Elm Pedersen,Søren Buus,Mogens H. Claesson,Ole Lund +14 more
TL;DR: This study demonstrates that present technology enables a fast global screening for T cell immune epitopes of potential diagnostics and vaccine interest, and includes immuno-bioinformatics predictors with the capacity to perform fast genome-, pathogen-, and HLA-wide searches for immune targets.
Journal ArticleDOI
Vaccination with p53-peptide–pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study
Inge Marie Svane,Anders Elm Pedersen,Hans Erik Johnsen,Dorte Nielsen,Claus Kamby,Eva Gaarsdal,Kirsten Nikolajsen,Søren Buus,Mogens H. Claesson +8 more
TL;DR: In conclusion, the strategy for p53-DC vaccination seems safe and without toxicity, and indications of both immunologic and clinical effect were found in heavily pretreated patients with advanced breast cancer.
Journal ArticleDOI
Induction of regulatory dendritic cells by dexamethasone and 1α,25-Dihydroxyvitamin D3
TL;DR: D3/Dex is an effective immunosuppressive drug combination for the induction of DCs capable of inducing T cell hyporesponsiveness.